Drug Approval | March 17, 2022
USFDA approves Rinvoq for ulcerative colitis
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
The investment will accelerate the overall Sarclisa development program
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
The meeting was co-organized by World Health Organization’s Country Office for India, World Animal Protection India and ReAct Asia Pacific
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
Machine learning approach to systems biology combined with ligand discovery platform
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Subscribe To Our Newsletter & Stay Updated
